The clinical benefit of hyperthermia in pancreatic cancer: a systematic review

References

• Netherlands Cancer Registry: [Figures about Cancer] (in Dutch). Available from: http://www.cijfersoverkanker.nl/selecties/Dataset_1/img59b5566ddcaf0 [last accessed 14 Sep 2017].
   Google Scholar
• SEER database. Available from: https://seer.cancer.gov/statfacts/html/pancreas.html [last accessed 9 Sep 2017].
   Google Scholar
• Neoptolemos JP, Palmer DH, Ghaneh P, et al. (2017). Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet 389:1011–24.
   PubMed Web of Science ®Google Scholar
• Oettle H, Post S, Neuhaus P, et al. (2007). Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 297:267–77.
   PubMed Web of Science ®Google Scholar
• Neoptolemos JP, Dunn JA, Stocken DD, et al. (2001). Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet 358:1576–85.
   PubMed Web of Science ®Google Scholar
• Casadei R, Di Marco M, Ricci C, et al. (2015). Neoadjuvant chemoradiotherapy and surgery versus surgery alone in resectable pancreatic cancer: a single-center prospective, randomized, controlled trial which failed to achieve accrual targets. J Gastrointest Surg 19:1802–12.
   PubMed Web of Science ®Google Scholar
• Golcher H, Brunner TB, Witzigmann H, et al. (2015). Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer: results of the first prospective randomized phase II trial. Strahlenther Onkol 191:7–16.
   PubMed Web of Science ®Google Scholar
• Versteijne E, van Eijck CHJ, Punt CJA, et al. (2016). Preoperative radiochemotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC trial): study protocol for a multicentre randomized controlled trial. Trials 17:127.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. (2017). Cancer statistics, 2017. CA Cancer J Clin 67:7–30.
   PubMed Web of Science ®Google Scholar
• Burris HA, 3rd, Moore MJ, Andersen J, et al. (1997). Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403–13.
   PubMed Web of Science ®Google Scholar
• Hidalgo M, Von Hoff DD. (2012). Translational therapeutic opportunities in ductal adenocarcinoma of the pancreas. Clin Cancer Res 18:4249–56.
   PubMed Web of Science ®Google Scholar
• Oei AL, Ahire VR, van Leeuwen CM, et al. (2017). Enhancing radiosensitisation of BRCA2-proficient and BRCA2-deficient cell lines with hyperthermia and PARP1-i. Int J Hyperthermia 19:1-10.
   Web of Science ®Google Scholar
• Ino Y, Yamazaki-Itoh R, Oguro S, et al. (2013). Arginase II expressed in cancer-associated fibroblasts indicates tissue hypoxia and predicts poor outcome in patients with pancreatic cancer. PLoS One 8:e55146.
   PubMed Web of Science ®Google Scholar
• Miyake K, Yoshizumi T, Imura S, et al. (2008). Expression of hypoxia-inducible factor-1alpha, histone deacetylase 1, and metastasis-associated protein 1 in pancreatic carcinoma: correlation with poor prognosis with possible regulation. Pancreas 36:e1–9.
   PubMed Web of Science ®Google Scholar
• Sun HC, Qiu ZJ, Liu J, et al. (2007). Expression of hypoxia-inducible factor-1 alpha and associated proteins in pancreatic ductal adenocarcinoma and their impact on prognosis. Int J Oncol 30:1359–67.
   PubMed Web of Science ®Google Scholar
• Couvelard A, O’Toole D, Leek R, et al. (2005). Expression of hypoxia-inducible factors is correlated with the presence of a fibrotic focus and angiogenesis in pancreatic ductal adenocarcinomas. Histopathology 46:668–76.
   PubMed Web of Science ®Google Scholar
• Suker M, Beumer BR, Sadot E, et al. (2016). A patient-level meta-analysis of FOLFIRINOX for locally advanced pancreatic cancer. Lancet Oncol 17:801–10.
   PubMed Web of Science ®Google Scholar
• Conroy T, Desseigne F, Ychou M, et al. (2011). FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364:1817–25.
   PubMed Web of Science ®Google Scholar
• Goldstein D, El-Maraghi RH, Hammel P, et al. (2015). nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. J Natl Cancer Inst 107:dju413.
   PubMedGoogle Scholar
• Von Hoff DD, Ervin T, Arena FP, et al. (2013). Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369:1691–703.
   PubMed Web of Science ®Google Scholar
• Ansari D, Kristoffersson S, Andersson R, Bergenfeldt M. (2017). The role of irreversible electroporation (IRE) for locally advanced pancreatic cancer: a systematic review of safety and efficacy. Scand J Gastroenterol 52:1165–71.
   PubMed Web of Science ®Google Scholar
• Rombouts SJ, Vogel JA, van Santvoort HC, et al. (2015). Systematic review of innovative ablative therapies for the treatment of locally advanced pancreatic cancer. Br J Surg 102:182–93.
   PubMed Web of Science ®Google Scholar
• Pandya GJ, Shelat VG. (2015). Radiofrequency ablation of pancreatic ductal adenocarcinoma: The past, the present and the future. World J Gastrointest Oncol 7:6–11.
   PubMed Web of Science ®Google Scholar
• Chuong MD, Springett GM, Freilich JM, et al. (2013). Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated. Int J Radiat Oncol Biol Phys 86:516–22.
   PubMed Web of Science ®Google Scholar
• Horsman MR, Overgaard J. (2016). The impact of hypoxia and its modification of the outcome of radiotherapy. J Radiat Res 57:i90–8.
   PubMed Web of Science ®Google Scholar
• Datta NR, Gómez Ordóñez S, Gaipl US, et al. (2015). Local hyperthermia combined with radiotherapy and-/or chemotherapy: recent advances and promises for the future. Cancer Treat Rev 41:742–53.
   PubMed Web of Science ®Google Scholar
• Overgaard J. (2011). Hypoxic modification of radiotherapy in squamous cell carcinoma of the head and neck-a systematic review and meta-analysis. Radiother Oncol 100:22–32.
   PubMed Web of Science ®Google Scholar
• Kirui DK, Koay EJ, Guo X, et al. (2014). Tumor vascular permeabilization using localized mild hyperthermia to improve macromolecule transport. Nanomedicine 10:1487–96.
   PubMed Web of Science ®Google Scholar
• van der Zee J. (2002). Heating the patient: a promising approach? Ann Oncol 13:1173–84.
   PubMed Web of Science ®Google Scholar
• Falk MH, Issels RD. (2001). Hyperthermia in oncology. Int J Hyperthermia 17:1–18.
   PubMed Web of Science ®Google Scholar
• Oei AL, Vriend LE, Krawczyk PM, et al. (2017). Targeting therapy-resistant cancer stem cells by hyperthermia. Int J Hyperthermia 33:419–27.
   PubMed Web of Science ®Google Scholar
• Hildebrandt B, Wust P, Ahlers O, et al. (2002). The cellular and molecular basis of hyperthermia. Crit Rev Oncol Hematol 43:33–56.
   PubMed Web of Science ®Google Scholar
• Hu Y, Li Z, Mi DH, et al. (2017). Chemoradiation combined with regional hyperthermia for advanced oesophageal cancer: a systematic review and meta-analysis. J Clin Pharm Ther 42:155–64.
   PubMed Web of Science ®Google Scholar
• Datta NR, Puric E, Klingbiel D, et al. (2016). Hyperthermia and radiation therapy in locoregional recurrent breast cancers: a systematic review and meta-analysis. Int J Radiat Oncol Biol Phys 94:1073–87.
   PubMed Web of Science ®Google Scholar
• Bai Z, Shi Y, Wang J, et al. (2017). Intratumoral radiofrequency hyperthermia-enhanced direct chemotherapy of pancreatic cancer. Oncotarget 8:3591–9.
   PubMed Web of Science ®Google Scholar
• Kirui DK, Celia C, Molinaro R, et al. (2015). Mild hyperthermia enhances transport of liposomal gemcitabine and improves in vivo therapeutic response. Adv Healthc Mater 4:1092–103.
   PubMed Web of Science ®Google Scholar
• Zhang T, Zhang F, Meng Y, et al. (2013). Diffusion-weighted MRI monitoring of pancreatic cancer response to radiofrequency heat-enhanced intratumor chemotherapy. NMR Biome 26:1762–7.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, Altman DG. The PRISMA Group (2009). Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. PLoS Med 6:e1000097.
   PubMed Web of Science ®Google Scholar
• Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. (2016). Rayyan-a web and mobile app for systematic reviews. Syst Rev 5:210.
   PubMed Web of Science ®Google Scholar
• Oxford Levels of Evidence Working Group. The Oxford 2011 Levels of Evidence. 2011 Available from: http://www.cebm.net/index.aspx?o=5653
   Google Scholar
• American Joint Committee on Cancer. (2010) Exocrine and endocrine pancreas. In: Compton CC, Byrd DR, Garcia-Aguilar J, et al., eds. AJCC Cancer Staging Manual 7th ed. New York: Springer, 241–250.
   Google Scholar
• Yu J, Blackford AL, Dal Molin M, et al. (2015). Time to progression of pancreatic ductal adenocarcinoma from low-to-high tumour stages. Gut 64:1783–9.
   PubMed Web of Science ®Google Scholar
• Dewhirst MW, Lee CT, Ashcraft KA. (2016). The future of biology in driving the field of hyperthermia. Int J Hyperthermia 32:4–13.
   PubMed Web of Science ®Google Scholar
• Horsman MR, Overgaard J. (2007). Hyperthermia: a potent enhancer of radiotherapy. Clin Oncol (R Coll Radiol) 19:418–20.
   PubMed Web of Science ®Google Scholar
• van den Tempel N, Horsman MR, Kanaar R. (2016). Improving efficacy of hyperthermia in oncology by exploiting biological mechanisms. Int J Hyperthermia 32:446–54.
   PubMed Web of Science ®Google Scholar
• Oei AL, Vriend LE, Crezee J, et al. (2015). Effects of hyperthermia on DNA repair pathways: one treatment to inhibit them all. Radiat Oncol 10:165.
   PubMed Web of Science ®Google Scholar
• Krawczyk PM, Eppink B, Essers J, et al. (2011). Mild hyperthermia inhibits homologous recombination, induces BRCA2 degradation, and sensitizes cancer cells to poly (ADP-ribose) polymerase-1 inhibition. Proc Natl Acad Sci USA 108:9851–6.
   PubMed Web of Science ®Google Scholar
• Bergs JW, Franken NA, Haveman J, et al. (2007). Hyperthermia, cisplatin and radiation trimodality treatment: a promising cancer treatment? A review from preclinical studies to clinical application. Int J Hyperthermia 23:329–41.
   PubMed Web of Science ®Google Scholar
• van Bree C, Beumer C, Rodermond HM, et al. (1999). Effectiveness of 2′,2′difluorodeoxycytidine (Gemcitabine) combined with hyperthermia in rat R-1 rhabdomyosarcoma in vitro and in vivo. Int J Hyperthermia 15:549–56.
   PubMed Web of Science ®Google Scholar
• Haveman J, Rietbroek RC, Geerdink A, et al. (1995). Effect of hyperthermia on the cytotoxicity of 2′,2′-difluorodeoxycytidine (gemcitabine) in cultured SW1573 cells. Int J Cancer 62:627–30.
   PubMed Web of Science ®Google Scholar
• Urano M. (1994). Thermochemotherapy: from in vitro and in vivo experiments to potential clinical application. In: Urano M, Douple E, eds. Hyperthermia and Oncology, Vol. 4: Chemopotentiation by Hyperthermia. Utrecht: VSP, 169–204.
   Google Scholar
• Gillen S, Schuster T, Büschenfelde CMZ, et al. (2010). Preoperative/Neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med 7:e1000267.
   PubMed Web of Science ®Google Scholar
• Kakehi M, Ueda K, Mukojima T, et al. (1990). Multi-institutional clinical studies on hyperthermia combined with radiotherapy or chemotherapy in advanced cancer of deep-seated organs. Int J Hyperthermia 6:719–40.
   PubMed Web of Science ®Google Scholar
• Yamada S, Takai Y, Nemoto K, et al. (1992). Intraoperative radiation therapy combined with hyperthermia for pancreatic carcinoma. Int J Oncol 1:795–8.
   PubMed Web of Science ®Google Scholar
• Ashayeri E, Bonney G, DeWitty RL, et al. (1993). Preliminary survivorship report on combined intraoperative radiation and hyperthermia treatments for unresectable pancreatic adenocarcinoma. J Natl Med Assoc 85:36–40.
   PubMed Web of Science ®Google Scholar
• Kouloulias VE, Nikita KS, Kouvaris JR, et al. (2001). Cytoreductive surgery combined with intraoperative chemohyperthermia and postoperative radiotherapy in the management of advanced pancreatic adenocarcinoma: feasibility aspects and efficacy. J Hepatobiliary Pancreat Surg 8:564–70.
   PubMedGoogle Scholar
• Kouloulias VE, Kouvaris JR, Nikita KS, et al. (2002). Intraoperative hyperthermia in conjunction with multi-schedule chemotherapy (pre-, intra- and post-operative), by-pass surgery, and post-operative radiotherapy for the management of unresectable pancreatic adenocarcinoma. Int J Hyperthermia 18:233–52.
   PubMed Web of Science ®Google Scholar
• Douwes FR. (2006). Thermo-chemotherapie des fortgeschrittenen Pankreaskarzinoms. Biologische Medizin 36:126–30.
   Google Scholar
• Bull JMC, Scott GL, Strebel FR, et al. (2008). Fever-range whole-body thermal therapy combined with cisplatin, gemcitabine, and daily interferon-α: a description of a phase I-II protocol. Int J Hyperthermia 24:649–62.
   PubMed Web of Science ®Google Scholar
• Ohguri T, Imada H, Yahara K, et al. (2008). Concurrent chemoradiotherapy with gemcitabine plus regional hyperthermia for locally advanced pancreatic carcinoma: initial experience. Radiat Med 26:587–96.
   PubMedGoogle Scholar
• Bakshandeh-Bath A, Stoltz AS, Homann N, et al. (2009). Preclinical and clinical aspects of carboplatin and gemcitabine combined with whole-body hyperthermia for pancreatic adenocarcinoma. Anticancer Res 29:3069–77.
   PubMed Web of Science ®Google Scholar
• Maluta S, Schaffer M, Pioli F, et al. (2011). Regional hyperthermia combined with chemoradiotherapy in primary or recurrent locally advanced pancreatic cancer: an open-label comparative cohort trial. Strahlenther Onkol 187:619–25.
   PubMed Web of Science ®Google Scholar
• Ishikawa T, Kokura S, Sakamoto N, et al. (2012). Phase II trial of combined regional hyperthermia and gemcitabine for locally advanced or metastatic pancreatic cancer. Int J Hyperthermia 28:597–604.
   PubMed Web of Science ®Google Scholar
• Tschoep-Lechner KE, Milani V, Berger F, et al. (2013). Gemcitabine and cisplatin combined with regional hyperthermia as second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer. Int J Hyperthermia 29:8–16.
   PubMed Web of Science ®Google Scholar
• Volovat C, Volovat SR, Scripcaru V, Miron L. (2014). Second-line chemotherapy with gemcitabine and oxaliplatin in combination with loco-regional hyperthermia (EHY-2000) in patients with refractory metastatic pancreatic cancer – Preliminary results of a prospective trial. Rom Rep Phys 66:166–74.
   Web of Science ®Google Scholar
• Maebayashi T, Ishibashi N, Aizawa T, et al. (2017). Treatment outcomes of concurrent hyperthermia and chemoradiotherapy for pancreatic cancer: Insights into the significance of hyperthermia treatment. Oncol Lett 13:4959–64.
   PubMed Web of Science ®Google Scholar
• Yamada S, Takai Y, Nemoto K, et al. (1992). Intraoperative radiation therapy combined with hyperthermia against pancreatic carcinoma. Tohoku J Exp Med 166:395–401.
   PubMed Web of Science ®Google Scholar
• Kouloulias VE, Nikita KS, Kouvaris JR, et al. (2002). Intraoperative hyperthermia and chemoradiotherapy for inoperable pancreatic carcinoma. Eur J Cancer Care (Engl) 11:100–7.
   PubMed Web of Science ®Google Scholar
• Bruggmoser G, Bauchowitz S, Canters R, et al. (2011). Quality assurance for clinical studies in regional deep hyperthermia. Strahlenther Onkol 187:605–10.
   PubMed Web of Science ®Google Scholar
• Bruggmoser G, Bauchowitz S, Canters R, et al. (2012). Guideline for the clinical application, documentation and analysis of clinical studies for regional deep hyperthermia: quality management in regional deep hyperthermia. Strahlenther Onkol 188[Suppl 2]:198–211.
   PubMed Web of Science ®Google Scholar
• Kok HP, Kotte ANTJ, Crezee J. (2017). Planning, optimisation and evaluation of hyperthermia treatments. Int J Hyperthermia 33:593–607.
   PubMed Web of Science ®Google Scholar
• Crezee H, van Leeuwen CM, Oei AL, et al. (2016). Thermoradiotherapy planning: integration in routine clinical practice. Int J Hyperthermia 32:41–9.
   PubMed Web of Science ®Google Scholar
• Kok HP, Wust P, Stauffer PR, et al. (2015). Current state of the art of regional hyperthermia treatment planning: a review. Radiat Oncol 10:196.
   PubMed Web of Science ®Google Scholar
• Paulides MM, Stauffer PR, Neufeld E, et al. (2013). Simulation techniques in hyperthermia treatment planning. Int J Hyperthermia 29:346–57.
   PubMed Web of Science ®Google Scholar